title: Commentary: psoriasis patients with a history of malignancy represent an important but overlooked study population.
abstract: The treatment of moderate to severe psoriasis often requires the administration of systemic agents. However, information is limited on the safety of systemic agents in patients with pre-existing cancers. We attempt to summarize the small body of data and urge organized study of this patient population.
authors.affiliation: Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Persad
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Levender
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D006801:Humans; D009369:Neoplasms / Q000150:complications*; D011565:Psoriasis / Q000150:complications* / Q000188:drug therapy*; D012449:Safety